Joanne Ino Hsu, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Allergic Agents | 1 | 2022 | 141 | 0.790 |
Why?
|
| Urticaria | 1 | 2022 | 150 | 0.780 |
Why?
|
| Clone Cells | 1 | 2018 | 1692 | 0.510 |
Why?
|
| Eye Diseases | 1 | 2019 | 669 | 0.470 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 654 | 0.430 |
Why?
|
| Cisplatin | 1 | 2018 | 1662 | 0.420 |
Why?
|
| Doxorubicin | 1 | 2018 | 2234 | 0.410 |
Why?
|
| Hematopoiesis | 1 | 2018 | 2073 | 0.340 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 3524 | 0.220 |
Why?
|
| Pancytopenia | 1 | 2023 | 104 | 0.210 |
Why?
|
| Bone Marrow Diseases | 1 | 2023 | 231 | 0.190 |
Why?
|
| Cyclosporine | 1 | 2022 | 788 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 498 | 0.170 |
Why?
|
| Thalidomide | 1 | 2022 | 890 | 0.150 |
Why?
|
| Acne Vulgaris | 1 | 2021 | 302 | 0.150 |
Why?
|
| Phosphoproteins | 2 | 2016 | 2441 | 0.140 |
Why?
|
| Mutation | 3 | 2022 | 29786 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 730 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13695 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1062 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1879 | 0.120 |
Why?
|
| Fungi | 1 | 2016 | 327 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 1276 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2016 | 912 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2022 | 3390 | 0.100 |
Why?
|
| Dermatology | 1 | 2021 | 872 | 0.100 |
Why?
|
| Chromatin | 1 | 2022 | 2934 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1832 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4208 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 1988 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2016 | 1939 | 0.080 |
Why?
|
| Proteome | 2 | 2016 | 1798 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2022 | 9145 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 5181 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10484 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 399 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 21833 | 0.050 |
Why?
|
| DNA Repair | 2 | 2022 | 2046 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2022 | 755 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2021 | 862 | 0.040 |
Why?
|
| Humans | 9 | 2023 | 744376 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 3252 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 1335 | 0.030 |
Why?
|
| Genome, Fungal | 1 | 2016 | 204 | 0.030 |
Why?
|
| Mice | 2 | 2018 | 81202 | 0.030 |
Why?
|
| Solid Phase Extraction | 1 | 2014 | 28 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 1035 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 808 | 0.030 |
Why?
|
| Phenotype | 2 | 2023 | 16367 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 2949 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 976 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 168770 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 2804 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 2751 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 163284 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8437 | 0.020 |
Why?
|
| Middle Aged | 1 | 2018 | 213388 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 13814 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 7182 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2023 | 12209 | 0.010 |
Why?
|
| Male | 1 | 2018 | 350118 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5717 | 0.010 |
Why?
|
| Female | 1 | 2018 | 380200 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 23406 | 0.010 |
Why?
|